(+)-Ketoconazole
CAS: 142128-59-4
Rif. 3D-SFA12859
| 1mg | Fuori produzione | ||
| 2mg | Fuori produzione | ||
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 100mg | Fuori produzione |
Informazioni sul prodotto
- 1-[4-[4-[[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]ethanone
- Piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, (2R-cis)-
- Piperazine, 1-acetyl-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-
- Ethanone, 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]-
(+)-Ketoconazole is a potent inhibitor of cancer cell growth and tumor formation. It works by blocking the activity of kinases, which are enzymes that regulate the cell cycle and promote cell division. This drug has been shown to inhibit the growth of various types of cancer cells, including those found in breast, lung, and prostate cancers. In addition, (+)-Ketoconazole has been used as an anticancer agent in Chinese medicinal practices due to its ability to induce apoptosis in human cancer cells. Urine studies have demonstrated that this drug can also inhibit protein kinase activity, further supporting its potential as a cancer treatment option. Overall, (+)-Ketoconazole is a promising inhibitor with strong potential for future research and development in the field of oncology.
